Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they “missed a filing.”
They lose because they misunderstood the system—how patents are examined, how exclusivity is interpreted, and how enforcement actually plays out across jurisdictions that don’t beh…

Pharmaceutical patent strategy is often discussed like a binary choice: fight for every right, or walk away early. But the real world is messier—and more expensive.
In a recent piece from DrugPatentWatch, the “cut / keep / cash” decision matrix reframe…

Most “commercial market access” pitches ignore the clock. That’s why they lose.
In pharma, timing isn’t a detail—it’s the deal.
A growing number of commercial market access vendors are still selling as if the market will wait politely for their value p…

Before You Launch: The Freedom-to-Operate (FTO) Reality Check for Pharma
In pharma, “we think we’re clear” is not a strategy. It’s a risk posture.
The market doesn’t care about your internal confidence interval. Regulators care about safety and efficac…

Pharma procurement teams spend a lot of time on price—rebates, contracting, tender strategy, and budget impact. But there’s a quieter, higher-stakes risk that often gets treated like an afterthought: Paragraph IV filings.
If you’re buying branded drugs…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline—or underwriting a deal—“patent life” is one of those phrases that sounds precise… until you try to use it across borders.
…